<< Go Back to NCF Events Page "LUNCHEON WITH THE EXPERTS" With Dr. Mintallah Haider No registration needed. Date: Oct 22, 2026 Time: Noon Eastern (9 AM Pacific) Here are the viewing options on Thursday, October 22nd, at Noon Eastern (9 AM Pacific): The Webinar will be live on Facebook Live (under Events) and YouTube Live . Drop your questions for Dr. Haider to answer in the comments on Facebook or chat on YouTube. “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — in neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join during their lunch break. Live sessions are recorded and will be available afterward. ABOUT MINTALLAH HAIDER, MD Gastrointestinal Oncologist Moffitt Cancer Center Dr. Haider is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center and an Associate Professor of Oncologic Sciences at University of South Florida. Dr. Haider received her Bachelor of Science as well as her Medical Degree at the University of Florida in Gainesville, FL. She completed an internship and residency in Internal Medicine at the University of Southern California in Los Angeles, CA followed by Hematology and Medical Oncology Fellowship at Moffitt Cancer Center University of South Florida in Tampa, FL. Dr. Haiders clinical practice is focused on neuroendocrine tumor (NET) oncology. As a member of the Endocrine Program Multidisciplinary team, she also treats paraganglioma and pheochromocytoma. In parallel, Dr. Haider leads and participates in clinical research focused on the systemic therapies of these tumors. As a Clinical Educator, she participates in the education of medical students, residents and fellows as well as community outreach. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), where she serves on the Continuing Education Committee and has been an invited moderator and speaker at NANETS national and regional seminars. Dr. Haider shares her expertise as a speaker at community medical societies as well as patient educational groups. She serves patients at Moffitt Cancer Center - Magnolia and Moffitt International Plaza. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Go back to the Podcast page EPISODE 16: TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM Download a Transcript of this Episode >> ABOUT THIS EPISODE In this special episode, Dr. Will Pegna shares 10 new and exciting discoveries from the 2022 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium. Each year, hundreds of medical professionals gather to share the latest in NET research and medical advances. LACNETS and Dr. Pegna discuss the Symposium highlights and why they matter to the NET community. MEET DR. GUILLAUME PEGNA Dr. Guillaume (Will) Pegna, MD is a Medical Oncologist at Oregon Health & Science University or OHSU in Portland, Oregon. Dr. Pegna specializes in the care of adults with cancers of the gastrointestinal (GI) and neuroendocrine systems (NETs). He is additionally interested and experienced in the management of rare tumors including pheochromocytomas, paragangliomas, and adrenocortical carcinomas. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy, and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys. Dr. Pegna grew up in Upstate New York in a French-speaking family and goes by either Guillaume or Will, the English translation of his name. Outside of work, he enjoys hiking, ice hockey, and traveling with his family. TOP 10 HIGHLIGHTS OF THE 2022 NANETS SYMPOSIUM REFERENCES 10. Oral abstract presentation by Lindsay Hunter, MD, Huntsman Cancer Institute: "Circulating tumor DNA using a personalized, tumor-informed assay in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumor patients." 9. Oral abstract presentation by Mehran Taherian, MD, MD Anderson: "High-grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathology and Molecular Characteristics." 8. Oral presentation by Aman Chauhan, MD, University of Kentucky Markey Cancer Center: “How to Define PRRT Refractory and Role of PRRT Repeat?” NET RETREAT: A Phase II RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in Midgut NET Courtesy of Aman Chauhan, MD 7. Oral presentation by Jaume Capdevila Castillon, MD, PhD, Hospital Universitari Vall d’Hebron, Spain: “Novel TKIs for GEP NETs” Courtesy of Jaume Capdevila MD, PhD Poster presentation by Satya Das, MD: "E fficacy and Toxicity of Anti-Vascular Endothelial Growth Factors (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) - A Systematic Review and Meta-Analysis." 6. Oral abstract presentation by Nancy Joseph, MD, PhD, University California, San Francisco: "TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors." 5. Oral abstract presentation by Taymeyah Al-Toubah, MPH, Moffitt Cancer Center: "Phase 2 Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors." 4. Oral abstract presentation by Eleonora Pelle, MD, Moffitt Cancer Center: "Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors." 3. Oral abstract presentation by Taymeyah Al-Toubah, MPH, Moffitt Cancer Center: "Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate." 2. Oral abstract presentation by Brendon Herring, MS, University of Alabama at Birmingham School of Medicine: "Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors." Oral abstract presentation by Farhana Moon, Sr Clinical Research Analyst, UCSF, Helen Diller Family Comprehensive Cancer Center: "Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)." 1.Oral presentation by Dr Ebrahim Delpassand, Excel Diagnostics: "Early Data on 212Pb-DOTAMTATE (Alpha PRRT)" ABOUT NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the NANETS October 27-29, 2022 Symposium, there are many more noteworthy abstracts found (or listed) here: Click here for NANETS Oral Abstracts Presentations Click here for NANETS Oral Abstracts in PDF format While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. CLINICAL TRIAL INFORMATION Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02) Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (CABINET) EXCEL Diagnostics (AlphaMedix, Alpha PRRT trial) RESOURCES https://www.youtube.com/watch?v=sgppSkk74p0 "NET Medical Therapies" with Dr. Hecht (October 6, 2022) https://www.youtube.com/watch?v=kZCd2zyn4fM "Exciting Advances in NET Management: Cu64 DOTATATE & Alpha PRRT" with Dr. Ebrahim S. Delpassand DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for 2026Conference_Speakers. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Back to the Conference Page 2026 Neuroendocrine Cancer Patient Conference SPEAKERS Chandana Banerjee, MD, MPA Associate Professor Department of Supportive Care Medicine, Hospice and Palliative Care Dean, Director and Designated Institutional Official, Graduate Medical Education, City of Hope Chandana Banerjee, M.D., M.P.A., HMDC, is the dean, director and designated institutional official for Graduate Medical Education at City of Hope ® . She is also an associate professor in the Department of Supportive Care Medicine , specializing in hospice and palliative care. She developed the City of Hope Hospice & Palliative Medicine Fellowship. She also established the Cancer Pain Rotation for Kaiser Permanente Los Angeles Hospice & Palliative Medicine Fellowship, which is now part of the core curriculum for the Kaiser Permanente Southern California Hospice & Palliative Medicine fellowship program. Dr. Banerjee also developed and directed the End of Life Symposium, which was first held at City of Hope in September 2019 and was endowed by Arthur Riggs, Ph.D. She is the physician lead for Schwartz Rounds at City of Hope and serves as chair on the End of Life Option Act Subcommittee. She is also a member of the Continuing Medical Education and the Ethics and Quality of Life committees. She is currently chair-elect of the American Academy of Hospice & Palliative Medicine's (AAHPM) Medical Aid in Dying Special Interest Group. She served as chair-elect, chair and past chair on the AAHPM Humanities and Spirituality Special Interest Group from March 2019-2022. She serves on AAHPM's Editorial Board for the publication AAHPM Quarterly and has served on the assembly's Abstract Review Board. She is a reviewer for evidence-based research articles in hospice and palliative care submitted to McMaster University in Canada. Dr. Banerjee has written and published numerous articles and book chapters and spoken at conferences nationally and internationally. She is the editor for an upcoming book by Springer Publishing's CTAR series exploring views on end-of-life care, death, burial and bereavement within different cultures and religions. She also sits on the board of directors for Compassion & Choices, an organization dedicated to end-of-life issues. Dr. Banerjee is a contributing member on the National Comprehensive Cancer Network Fatigue Panel. Her leadership activities in education include excellence in teaching, faculty development and mentoring, and curriculum and program development. Dr. Banerjee earned her undergraduate degree with an honors scholar designation from University of Connecticut. She received her master's degree in public administration from New York University and her medical degree from Saba University School of Medicine. She completed her residency in pediatrics and her fellowship in adult hospice and palliative medicine from Kaiser Permanente Los Angeles. She is also a Hospice Medical Director Certified. Dr. Banerjee was recently selected as a Health Equity Scholar into the prestigious Cambridge Health Alliance — Center for Health Equity Education & Advocacy Program’s 2021-2022 Cohort. Dr. Banerjee loves to write poetry and her first collection, "Ashen Leaves," was published in July 2020. Her second book of poems, "Neruda in Bed," was published in November 2021. Jennifer Chan, MD, MPH Medical Oncologist Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been the principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and the current Vice President of NANETS. She serves on the National Comprehensive Center Network (NCCN) Neuroendocrine Tumors Guidelines Panel. Dr. Chan is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. Chandrikha Chandrasekharan, MBBS Medical Oncologist Clinical Associate Professor University of Texas MD Anderson Cancer Center Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Dr. Chandrasekharan earned her medical degree from Kilpauk Medical College in India. She completed her internal medicine residency at the University of Florida College of Medicine in Jacksonville, followed by a fellowship in Palliative Medicine at Mayo Clinic, Rochester. She then pursued a fellowship in Medical Oncology at LSU Shreveport, and further specialized in gastrointestinal malignancies with an additional year of training at Mayo Clinic, where she developed a strong interest in neuroendocrine tumors. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care. Delphine Chen, MD Director of Molecular Imaging and Therapy Professor, Clinical Research Division & Professor of Radiology Fred Hutch Cancer Center UW Medicine Dr. Delphine L. Chen is a nuclear medicine physician-scientist with more than 20 years of broad clinical expertise in all types of positron emission tomography (PET) and nuclear medicine molecular imaging diagnostic tests and therapy. She is particularly interested in how molecular imaging can provide information about cancer behavior and affect treatment decisions. Dr. Chen graduated from the Washington University School of Medicine and subsequently completed a postdoctoral research fellowship studying novel inflammation imaging PET methods. She then completed a nuclear medicine residency at Barnes-Jewish Hospital. Dr. Chen was the principal investigator in the first in-human trial of PARP radiotracers to predict which patients will respond to PARP inhibitors, now shown to be highly effective in BRCA mutation-driven breast cancers. Her research seeks to expand the field of nuclear medicine and find new diagnostic imaging and therapy agents for clinical trials, including focusing on how PARP radiotracers can be used to identify additional patients who may respond to anticancer drugs. In 2006, she received an NIH career development award and the Damon Runyon Cancer Research Foundation Clinical Investigator Award, and later a Doris Duke Charitable Foundation Clinical Investigator Award, in support of her research into PET imaging and has continued to receive NIH funding since. And in 2021, the Academy for Radiology and Biomedical Imaging Research named Dr. Chen a Distinguished Investigator. She has contributed to multiple publications and has more than 300 citations and is a member of the Institute for Prostate Cancer Research, a collaborative effort between Fred Hutch and UW Medicine. Dr. Chen is board-certified in nuclear medicine by the American Board of Nuclear Medicine. Callisia Clarke, MD, MS, FACS, FSSO Chief of Surgical Oncology Associate Professor of Surgery Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. In 2024 President Biden announced her appointment as a Member of the National Cancer Advisory Board. Dr. Clarke plays a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and helping advance breakthroughs to prevent, detect, and treat diseases like cancer. Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist National Cancer Institute National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Udhayvir Singh Grewal, MBBS Medical Oncologist Emory Winship Cancer Institute Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. Thorvardur Halfdanarson, MD Hematologist, Oncologist Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is President Emeritus of the North American Neuroendocrine Tumor Society (NANETS) as well. Julie Hallet, MD, MSc, FRCSC, FACS, FSSO Surgical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre Associate Professor of Surgery, University of Toronto Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. Pamela Kunz, MD Gastrointestinal Oncologist Yale Medicine Dr. Pamela Kunz is a Professor of Medicine at Yale School of Medicine where she serves as the Division Chief of GI Medical Oncology and Director of the Center for GI Cancers at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She serves as the Editor-in-Chief of JCO Oncology Advances and has previously held other leadership roles in the field including member of the FDA’s Oncology Drug Advisory Committee, President of the North American Neuroendocrine Tumor Society, and Chair of the Neuroendocrine Tumor Taskforce of the NCI. She was awarded ‘Woman Oncologist of the Year’ in 2021 by Women Leaders in Oncology. X @PamelaKunzMD Daneng Li, MD Medical Oncologist City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. Sheila Lindsay, NP, MSN, RN Gastrointestinal Medical Oncology University of California San Francisco Sheila Lindsay is a nurse practitioner at the University of California San Francisco where she sees patients with neuroendocrine tumors and other gastrointestinal malignancies. She helps patients manage the side effects of cancer and its treatments. She also helps to educate patients on how to optimize their health and quality of life while undergoing therapy and during recovery. She is part of the multidisciplinary team at the Center for Neuroendocrine Tumors at UCSF where she works closely caring for patients undergoing therapies including PRRT. She earned her bachelor’s degree in nursing from Creighton University in Omaha, Nebraska followed by a master’s degree from the University of California San Francisco School of Nursing Adult Nurse Practitioner program. Josh Mailman, MBA President NorCal CarciNET Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI). Josh is also a member of National Cancer Institute’s GI Steering Committee and serves as co-chair of the Patient Advocate Steering Committee. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures. Erik Mittra, MD, PhD Nuclear Medicine Physician Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Guillaume Pegna, MD Assistant Professor of Medicine Division of Hematology/Medical Oncology Oregon Health & Science University Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys. Victoria Ramirez, LCSW Licensed Clinical Social Worker Victoria Ramirez, LCSW is a Licensed Clinical Social Worker with over 14 years of experience supporting individuals navigating cancer, chronic illness, grief, and major life transitions. She specializes in working with patients and families impacted by oncology diagnoses, as well as those coping with loss, anxiety, and unexpected life changes. Victoria earned her Master of Social Work from the University of Southern California and is licensed in California. Her therapeutic approach is integrative, drawing primarily from client-centered therapy and cognitive behavioral therapy (CBT) to meet each individual’s unique needs. She is known for creating a calm, supportive, and judgment-free environment where clients feel safe to explore their experiences. With a warm and empathetic style, Victoria collaborates with clients to set both short- and long-term goals, adapting them as needs evolve over time. She is deeply committed to helping individuals build resilience, gain clarity, and feel supported throughout their healing journey. Michael C. Soulen, MD, FSIR, FCIRSE Interventional Radiologist Penn Medicine Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Jason Starr, DO Hematologist/Oncologist Mayo Clinic Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship. Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology. "The greatest joy of my career is the interaction and relationships I am able to have with my patients," says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief. Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic's conviction to hope, faith, and science. Back to the Conference Page

Join NCF for Atlanta_Speakers. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page Back to the Conference Page 2026 Neuroendocrine Cancer Patient Conference in Atlanta Heather Cole, MD Assistant Professor Radiology & Radiological Sciences Associate Program Director Nuclear Medicine Residency & Fellowship Programs Vanderbilt University School of Medicine Heather Cole, MD, joined VUMC Radiology faculty as an Assistant Professor in 2024. She specializes in Nuclear Medicine and Image Guided Procedures. Currently, Dr. Cole serves as Director for the Neuroendocrine Tumor Board at Vanderbilt , the Associate Program Director for the Nuclear Medicine Residency and Fellowship Programs and the Nuclear Medicine Education Director for the Diagnostic Radiology Residency Program. She is the Director of the FCC Radiology elective course through Vanderbilt University School of Medicine. Dr. Cole received her undergraduate degree from Colorado State University and went to medical school at the University of Tennessee Health Science Center. She completed her residency here at Vanderbilt University Medical Center. During her residency, Dr. Cole was conference chief (2023-2024), received the "Radiology Resident of the Year" award (2023-2024), as well as the "Radiology Resident Teacher of the Year" award (2022). As a trainee, she helped start an ultrasound clinic within Shade Tree Clinic. Seth J. Concors, MD, FACS, FSSO Gastrointestinal Surgical Oncology Emory University Seth Concors, MD is an academic surgical oncologist at Emory University and the Winship Cancer Institute, where he serves as Associate Program Director for both the General Surgery Residency and the Complex General Surgical Oncology Fellowship, and Director of the Surgical Oncology Research Fellowship. He leads Emory’s Peritoneal Surface Malignancy and Neuroendocrine Tumor surgical programs, with clinical and research interests focused on gastrointestinal neuroendocrine tumors, cytoreductive surgery/HIPEC, and survivorship outcomes. Dr. Concors is actively involved in national surgical societies including SSO, SSAT, NANETS, ACS, and ECOG-ACRIN, and his work emphasizes multidisciplinary collaboration, prospective outcomes research, and surgical education. He is committed to advancing patient-centered cancer care while mentoring the next generation of surgical oncologists. Po Hien Ear, PhD Scientist Associate Professor Department of Hematology and Medical Oncology Emory University Dr. Ear is an Associate Professor in the Department of Hematology and Medical Oncology. She is the Leader of the NET Research Team at the Emory Winship Cancer Institute. Dr. Ear is internationally renowned for her groundbreaking work on establishing NET 3D cultures and patient-derived xenograft models, elucidating NET tumor biology, and pioneering novel therapeutic approaches for neuroendocrine cancers. Dr. Ear has received numerous external grants to support her research. Currently, she serves as the Basic Science Principal Investigator for Project 3 of the NET SPORE (Specialized Program of Research Excellence), which focuses on determining the impact of GLP-1 drugs on small bowel and pancreatic NETs. In addition, she receives funding from the NET Research Foundation and the Department of Defense to investigate the mechanisms underlying NET resistance to anticancer therapies and to develop novel agents that specifically target and eliminate NET cancer cells. Udhayvir Singh Grewal, MD Medical Oncologist Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. Garima Gupta, MD Medical Oncologist University of Alabama Birmingham O'Neal Cancer Center Dr. Garima Gupta is an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. Her clinical practice focuses on patients with GI malignancies and Neuroendocrine Tumors. Dr. Gupta graduated from St. George's University with her medical degree in 2010. She then moved to the National Institutes of Health in Bethesda, Maryland and trained with Dr. Karel Pacak on Pheochromocytoma and Paraganglioma. She served as a third year chief resident during her Internal Medicine training and was awarded the Deepak Bhandari award for research and academic excellence. Following this, she completed her Hematology/Oncology fellowship at Markey Cancer Center, University of Kentucky and was mentored by Dr. Lowell Anthony on Neuroendocrine Tumors. She received a letter of achievement for academic excellence and research excellence award at University of Kentucky. Dr. Gupta now co-leads the NET multidisciplinary clinic at UAB and serves as the medical director of the inpatient Oncology consult service. Daniel M. Halperin, MD Medical Oncologist Associate Professor & Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology Emory University A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in complex multidisciplinary care for neuroendocrine cancers. He has expertise in applying immunotherapy and radioligand therapy to treat patients with neuroendocrine tumors (NETs). He is a member of the gastrointestinal oncology team at Winship Cancer Institute at Emory Midtown. Dr. Halperin is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. As vice chair of clinical affairs, he works with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department. Dr. Halperin received his medical degree from Weill Cornell Medical College in New York City, New York. He completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas. Meghan A. Lilly, MD Interventional Radiologist Emory University Dr. Lilly currently serves as the Site Director of Interventional Radiology at Winship Emory Midtown and Associate Chief of Radiology at Emory Midtown. Her professional focus is Interventional Oncology, meaning she provides a range of minimally invasive diagnostic and therapeutic procedures for patients with cancer. This includes the collaborative care for patients with Neuroendocrine Cancer. Saima Muzahir, MD, FCPS, FRCPE Nuclear Medicine Physician Emory University Hospital Saima Muzahir, MD, FCPS (Fellow college of Physicians and Surgeons Pakistan), FRCPE (Fellow Royal College of Physicians Edinburgh) is Associate professor of Radiology; serving as Enterprise Theranostics lead in the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta Georgia. Dr Muzahir is the Associate Program Director for Emory Molecular Imaging and Therapy (MIT) fellowship. She is the program manager for RAD-AID Pakistan and is currently serving as the vice president for Pakistan Society of Nuclear Medicine (PSNM). Dr Muzahir received her medical degree from Nishtar Medical College Pakistan and completed a four-year residency in Nuclear Medicine at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore Pakistan. After completing her training in Pakistan, she moved to the United States and did residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics, Iowa City, followed by a PET-CT fellowship from University of Wisconsin Madison. Dr. Muzahir is a Board of Director for SNMMI General Clinical Nuclear Medicine Council and also serves as a Director for American Board of Nuclear Medicine. Dr Muzahir’s research interests include radioligand therapies and oncologic PET-CT imaging. Back to the Conference Page

Watch educational videos about neuroendocrine cancer, including expert presentations, treatment information, patient stories, webinars, and support resources. Neuroendocrine Cancer Video Library This video library contains 400+ videos organized by NET topics. EDUCATIONAL VIDEOS Monthly Patient Educational Events Annual Educational Patient Conferences PRRT: Peptide Receptor Radionuclide Therapy High Grade NENs Newly Diagnosed Liver Directed Therapy Symptom Management Lung NET Medical Treatments/ Sequencing Treatments Research/ Clinical Trials NET Testing Surgery Diarrhea NET Imaging Pheo/Para Videos en Espanol Carcinoid Heart Disease BE INSPIRED Above & Beyond Awards Giovanna Joyce Imbesi, LACNETS Founder Inspirational Patient Advocacy Patient/Caregiver Stories WELLNESS & CAREGIVING Nutrition Wellness Caregiving/Palliative/ Supportive Care Music Heals

<< Back NIH/NCI Natural History Study for Neuroendocrine Neoplasms Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

<< Go back to the Podcast page EPISODE 18: MENTAL HEALTH & NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. MEET DR. KAREN KERSTING Karen Kersting, PhD, is a licensed clinical psychologist who provides counseling and psychotherapy to patients treated by surgeons in the Division of Surgical Oncology at the Medical College of Wisconsin. She completed an undergraduate degree in Journalism at the University of Wisconsin—Madison, a PhD in Counseling Psychology at Virginia Commonwealth University in Richmond, VA, and a postdoctoral fellowship in clinical health psychology at the Dayton Veterans Administration Medical Center in Dayton, OH. She joined the faculty of MCW in 2016. Dr. Kersting’s research interests include the development and assessment of integrated psychosocial services for people coping with cancer diagnosis and treatment, with an emphasis on patients diagnosed with cancer of the pancreas. Additionally, her work aims to highlight issues related to social determinants of health and Acceptance and Commitment Therapy interventions. TOP 10 QUESTIONS 1. How common are mental health issues in NET patients? What are the most common mental health issues you see in NET and what can be done about it? 2. How does anxiety impact NET patients? Why is it so prevalent in these patients? When do I know I need to reach out for support with my anxiety? What does treatment for anxiety look like? 3. How does depression impact NET patients? 4. What kind of sleep problems do you see in NET patients? 5. How do you work with patients who have long periods of fatigue? 6. How can a psychologist help people who are struggling to eat after treatment? 7. How can a patient, loved one, or physician tell the difference between a symptom such as fatigue or anxiety caused by NET tumors vs. a psychological trigger? Does it matter? How does one’s mental health impact one’s NET disease or the effectiveness of treatments? 8. Discuss how NET may impact young adult NET patients? How does NET impact young adult children, teenagers, and young children of NET patients? 9. Who should see a psychologist? When should someone see a psychologist? How does one find a psychologist? What should a patient expect when they come for a first visit with a mental health professional such as a psychologist, therapist, social worker or other? 10. What coping strategies or advice do you have for NET patients? What coping strategies or advice for family members or loved ones? RESOURCES READ Acceptance and Commitment Therapy Dr. Kersting's Publications Elephant & Tea Magazine JOIN AYA Neuroendocrine Cancer Group (Young Adult Private Facebook Group) LACNETS RESOURCES Wellness Resources Resources for Children Grief Resources Caregivers DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Paltusotine in Carcinoid Syndrome << Back CAREFNDR: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome CLINICALTRIALS.GOV IDENTIFIER: NCT05361668 DRUG/TREATMENT: Paltusotine PHASE: 3 STATUS: Recruiting SPONSOR: Crinetics Pharmaceuticals Inc. https://www.youtube.com/watch?v=jsfL7Vc_a1I DESCRIPTION: Crinetics is sponsoring a phase 3 clinical study for adults living with carcinoid syndrome associated with NETs. The purpose of this study is to test how safe and effective an oral, once-a-day, investigational study drug called paltusotine is in people living with carcinoid syndrome associated with NETs. The study will look at whether paltusotine can reduce carcinoid syndrome symptoms (such as flushing and bowel movements) compared with placebo. Also, the study will evaluate if the study drug has any antitumor effect. Download the CAREFNDR Brochure >>> Download 'CONNECT with Crinetics Patient Advocacy' Brochure >>> Update from the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland (March 5-7, 2025): Paltusotine_ENETS 2025 .pdf Download PDF • 356KB Dr. Aman Chauhan Discusses Paltusotine in Carcinoid Syndrome UPDATE (Mar 12, 2024): On Tuesday, March 12, 2024, Crinetics Pharmaceuticals announced positive topline results from their Phase 2 study of Paltusotine, a once-daily pill, under investigation for the treatment of carcinoid syndrome. The results show that Paltusotine was generally well-tolerated and reduced the frequency and severity of bowel movements and flushing. The company plans to engage the FDA to initiate a Phase 3 trial by the end of 2024. To read the announcement, go to the March 12, 2024 press release . To view the live webcast discussing the data and slides, go to the Paltusotine Study Results Presentation . UPDATE (Dec 18, 2023): On Monday, December 18, 2023, Crinetics announced positive initial findings from their ongoing open-label phase 2 study of paltusotine for the treatment of carcinoid syndrome. Today's announcement states “These initial results show the potential of paltusotine to significantly reduce both frequency and intensity of bowel movements and flushing, the key carcinoid syndrome symptoms. Further, paltusotine was well-tolerated and the overall pharmacokinetic profile was consistent with prior studies. After completing this Phase 2 study next quarter, we anticipate sharing the results with the FDA to align on the design of a Phase 3 program.” To read the announcement, go to the December 18, 2023 press release . To view the slides from the announcement, go to the, " CRINETICS INITIAL FINDINGS FROM ONGOING OPEN-LABEL PHASE 2 STUDY OF PALTUSOTINE FOR THE TREATMENT OF CARCINOID SYNDROME " . UPDATE (Sep 10, 2023): On Sept 10, 2023, Crinetics Pharmaceuticals announced positive results for their paltusotine phase 3 acromegaly study. This is the same once-daily pill that is currently in a phase 2 study for NET patients with carcinoid syndrome. To read the announcement, go to https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/ . For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Crinetics Clinical Trials EMAIL: clinicalstudies@crinetics.com PHONE: 833-827-9741

ABOUT CRINETICS At Crinetics Pharmaceuticals, our singular focus is on transforming the lives of patients living with endocrinology-related conditions. Our goal is to discover, develop, and commercialize novel therapeutics that leverage our unique understanding of endocrinology and G-protein coupled receptors (GPCRs). Endocrinology impacts nearly every aspect of human health, and our passion for this work runs deep. Our novel molecules that have been purposefully designed by our world-class, in-house R&D team have the potential to lift the burden of disease across a wide range of endocrine diseases and endocrine-related tumors so that patients can focus on life. Learn about Crinetics work in Carcinoid Syndrome >> Learn more about Crinetics and our groundbreaking work here >> RESOURCES FROM CRINETICS EVERYDAY ADVOCACY Download the Everyday Advocacy Brochure >>> Visit EverydayAdvocacy.com >>> CAREFNDR Clinical Study Download the CAREFNDR Brochure >>> Learn More About CAREFNDR on the NCF Clinical Trials Page >>> BRAVESST Clinical Study Download the BRAVESST Brochure >>> Learn More About BRAVESST on the NCF Clinical Trials Page >>> This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment.

Join NCF for Apr2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=JkH2Jsvc1Co Download the Transcript Here >>> ABOUT Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. ABOUT DR. EDWARD WOLIN DR. Edward Wolin Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai. The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology. During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. MEET DR. WILLIAM C. CHEN Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. MEET DR. ALEXANDRA HOTCA-CHO Dr. Hotca specializes in treating gastrointestinal cancers, with expertise in advanced radiation therapy techniques such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and respiratory gating. These approaches are designed to optimize treatment outcomes and minimize side effects. Her research focuses on enhancing patient quality of life through preventive strategies and identifying predictive biomarkers for radiation-induced toxicities. Dr. Hotca is dedicated to providing exceptional care to the diverse patient community at UCSF. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY: 1. What is radiation oncology? How does it work? How is it different from other types of radiation? 2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective? Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used? Is there a number or size limit of the tumor(s)? 4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it? If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT? If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated? How common is increased pain after treatment to the bone? What causes that? 5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?) Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans? How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they? Is there a risk with fertility? What other risks are there? 6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give? 9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor? How do you know if the treatment “worked”? Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment? RESOURCES READ Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go Back to NCF Events Page "LUNCHEON WITH THE EXPERTS" With Dr. Jonathan Strosberg No registration needed. Date: July 23, 2026 Time: Noon Eastern (9 AM Pacific) Here are the viewing options on Thursday, July 23rd, at Noon Eastern (9 AM Pacific): The Webinar will be live on Facebook Live (under Events) and YouTube Live . Drop your questions for Dr. Strosberg to answer in the comments on Facebook or chat on YouTube. “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — in neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join during their lunch break. Live sessions are recorded and will be available afterward. ABOUT JONATHAN STROSBERG, MD Gastrointestinal Oncology Moffitt Cancer Center, Tampa, Florida Jonathan Strosberg, MD, is a professor in the Department of Gastrointestinal Oncology at the Moffitt Cancer Center in Tampa, FL, specializing in the management of neuroendocrine malignancies. He is also section head of the Neuroendocrine Tumor Division at the Moffitt Cancer Center. He is a graduate of Harvard University and Weill Cornell Medicine. He completed his fellowship in medical oncology and hematology at the Moffitt Cancer Center. Dr. Strosberg has published more than 20 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in The New England Journal of Medicine , the Journal of Clinical Oncology and The Lancet Oncology . He has also authored 13 articles for UpToDate . He has served as president of the North American Neuroendocrine Tumor Society, and he serves on the National Comprehensive Cancer Network Neuroendocrine Guidelines Committee. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page